Cyclo Therapeutics, Inc. (CYTH) Misses Q2 EPS by 7c

Cyclo Therapeutics, Inc. (NASDAQ: CYTH) reported Q2 EPS of ($0.41), $0.07 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $542 thousand versus the consensus estimate of $571 thousand.

For earnings history and earnings-related data on Cyclo Therapeutics, Inc. (CYTH) click here.

You May Also Be Interested In

• Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
• Bernstein SocGen Group Downgrades China Resources Beer Holdings Co Ltd. (291:HK) (CRHKY) to Market Perform
• UBS Upgrades SolarEdge (SEDG) to Buy